Form 4: Anika Therapeutics EVP David Colleran Reports Stock Transactions
SEC Form 4
David Colleran, EVP, General Counsel, and Corporate Secretary of Anika Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On March 11, 2024, David Colleran, EVP, General Counsel, and Corporate Secretary of Anika Therapeutics, reported transactions involving Anika Therapeutics (ANIK) common stock.
- These transactions included the vesting of restricted stock units (RSUs) and the subsequent disposition of shares to satisfy tax withholding obligations.
- Colleran acquired 3,682 shares, 5,465 shares, and 7,662 shares through the vesting of RSUs at a price of $0.
- He also disposed of 1,081 shares and 1,605 shares at $25.42 and 2,250 shares at $25.79 to cover tax obligations.
- Following these transactions, Colleran directly owns 32,995 shares of Anika Therapeutics common stock.
- The RSUs vest in three equal annual installments.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common for executives who receive stock-based compensation. It provides transparency to the market regarding the trading activities of company insiders.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives.
- The vesting schedules and tax withholding practices are typical for RSU grants.
- Comparable companies like Zimmer Biomet, Stryker, and Johnson & Johnson also have executives who regularly file Form 4s related to stock options and RSU vesting.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- The sale of shares to cover tax obligations may slightly increase the trading volume of the stock.
Key Dates
| Date | Description |
|---|---|
| 03/09/2021 | Date of grant for RSUs vesting in three equal annual installments. |
| 03/09/2022 | First vesting date for RSUs granted on March 9, 2021. |
| 03/11/2022 | Date of grant for RSUs vesting in three equal annual installments. |
| 05/12/2023 | Colleran acquired 642 shares under the Anika Therapeutics, Inc. Employee Stock Purchase Plan. |
| 03/09/2023 | Date of grant for RSUs vesting in three equal annual installments. |
| 11/14/2023 | Colleran acquired 192 shares under the Anika Therapeutics, Inc. Employee Stock Purchase Plan. |
| 03/08/2024 | Closing price of ANIK common stock was $25.42. |
| 03/09/2024 | Vesting date for RSUs granted on March 9, 2023. |
| 03/11/2024 | Date of reported transactions: vesting of RSUs and sale of shares for tax obligations. |
| 03/11/2024 | Closing price of ANIK common stock was $25.79. |
| 03/12/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.